Investment
Features
FeesSafety
Academy
More
Pluang+

Compare US Global Jets ETF (JETS) vs Eli Lilly And Co (LLY) Price & Performance

US Global Jets ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

US Global Jets ETF vs Eli Lilly And Co — how do they compare? US Global Jets ETF trades at $30.58, while Eli Lilly And Co trades at $1,163.35 (market cap $1.02T). The key difference: Eli Lilly And Co pays a 0.6% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals.

JETSLLY
Sector
Sector/ThematicHealth
52-Week High
$33.34$1.24K
52-Week Low
$23.12$625.65
Market Cap
$1.02T
Enterprise Value
$1.06T
Dividend Yield
0.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

US Global Jets ETF

JETS trades at $30.58, up 0.39% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF faces headwinds from rising fuel costs as U.S. airlines spent $6.66 billion on jet fuel in May 2026 (U.S. Transportation Department, July 2026), though falling oil prices recently provided some relief. Technical indicators show RSI levels in oversold territory at 24.66 for the 12-day period, suggesting potential buying opportunity.

The outlook remains cautious as airline profits face pressure from fuel volatility and Middle East conflict impacts. While lower oil prices offer temporary relief, the sector's cyclical nature and competitive dynamics with defense-focused ETFs present ongoing challenges. Investment opportunity exists for those betting on travel recovery, but risks from fuel price shocks and operational disruptions require careful monitoring.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About US Global Jets ETF

JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.

Read more on JETS

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY